Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinson's Disease With Motor Fluctuations Clear all
Completed Phase 2 Interventional Results available

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

NCT01515410
View directory record Official record
Conditions
Parkinson's Disease, Motor Fluctuations
Interventions
DM-1992, Sinemet IR
Drug
Lead sponsor
Depomed
Industry
Eligibility
30 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

NCT02542696
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

NCT02352363
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 3 Interventional Results available

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

NCT00664209
View directory record Official record
Conditions
Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
Interventions
clartihromycin, amoxicillin, and omeprazole, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02242487
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 86 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

NCT00165789
View directory record Official record
Conditions
Parkinson's Disease
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Little Rock, Arkansas • Oxnard, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT02687542
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jul 24, 2026, 5:19 PM EDT
Completed No phase listed Observational

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

NCT02611713
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations

NCT03608371
View directory record Official record
Conditions
Parkinson Disease, Motor Disorder
Interventions
BTRX-246040, Placebo
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
30 Years to 76 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Hallandale, Florida • Farmington Hills, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

NCT02224664
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

NCT03051607
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Tozadenant
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

NCT03187301
View directory record Official record
Conditions
Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions
APL-130277, Placebo, Moxifloxacin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

NCT00203164
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Jul 24, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional Results available

A Study of E2007 In Patients With Parkinson's Disease

NCT00427011
View directory record Official record
Conditions
Parkinson's Disease
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Peoria, Arizona • Little Rock, Arkansas • Oxnard, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 24, 2026, 5:19 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT07432958
View directory record Official record
Conditions
Parkinson Disease
Interventions
AP-472, Placebo
Drug · Other
Lead sponsor
Appello Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Active, not recruiting Phase 3 Interventional

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVN424 75 mg, CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

NCT06055985
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, UCB0022
Other · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
35 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 24, 2026, 5:19 PM EDT
Not listed Phase 3 Interventional

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

NCT00260793
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ropinirole Hydrochloride
Drug
Lead sponsor
Agarwal, Pinky, M.D.
Individual
Eligibility
25 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2006 · Synced Jul 24, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

NCT03292016
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277, APO-go, Apokyn
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boca Raton, Florida • Port Charlotte, Florida • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Jul 24, 2026, 5:19 PM EDT